Biotech Startups

Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders. Its lead indication is trichotillomania, and its work extends to other obsessive-compulsive, addictive, and CNS conditions.

2 investors

ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics that target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's. The company operates in the biotechnology and neurology therapeutics space.

2 investors

2 investors

Propeller Bio discovers and develops biologic therapeutics that target multiple disease-driving pathways to achieve synergistic effects, aimed at patients with unmet medical needs. The company operates in the drug discovery and development space and is based in the Bay Area, California.

2 investors

Protalix is a biopharmaceutical company that develops and manufactures innovative pharmaceutical products, including treatments for orphan and rare diseases. The company leverages its proprietary technology platform and extensive expertise in drug development, regulatory affairs, and pharmaceutical manufacturing.

2 investors

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.

2 investors

Proteina develops single-molecule protein-protein interaction (PPI) detection technology (SPID) that generates real-time, high-resolution data to support therapeutic drug development. The company applies PPI analysis toward precision medicine.

2 investors

Protera builds functional protein ingredients for the food industry using its madi platform, which combines generative AI and computational biology to design novel proteins produced through precision fermentation. Its applications range from food products to advanced materials.

2 investors

ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence. Its work spans ex vivo cell therapy (ProT-096) and in vivo biologic programs (RGT-096).

2 investors

Prothea Technologies develops fluorescence imaging and optical sensing technologies for respiratory medicine and oncology applications. The company creates medical devices and diagnostic platforms focused on advancing clinical validation and regulatory approval for respiratory and cancer care.

2 investors

Proveca is a paediatric-focused pharmaceutical company that develops, licenses, and distributes medicines designed specifically for children, including conducting clinical trials for safety, efficacy, and age-appropriate formulations. It serves healthcare providers, carers, and paediatric patients, with a global ambition across the US, Canada, Europe, and Japan.

2 investors

Sanofi is a pharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients globally. The company operates in over 100 countries with a focus on breakthrough science and healthcare innovation.

2 investors

Provolut offers an AI-based web app for protein design that predicts protein evolutions and generates candidate variants from a client's starting dataset, aiming to achieve target protein attributes with far fewer lab experiments than methods like directed evolution or deep mutational scanning. It serves pharma, biotechnology, and research organizations, with on-premises or API deployment options.

2 investors

Proxima is a biotech company developing proximity therapeutics through a drug discovery engine and a structural proteomics data platform.

2 investors

Proxima Bio is an early-stage biotechnology company developing protein degradation technology to target previously undruggable proteins for treatment of autoimmune conditions and cancers. The company is spun out of WEHI (Walter and Eliza Hall Institute) and based in Melbourne, Australia.

2 investors

PsiThera is a biotechnology company using computational and physics-based methods—including quantum mechanics, molecular dynamics, machine learning, and simulation—for mechanism-driven drug design and discovery. Its work spans computational chemistry, immunology, and translational research to advance novel therapeutics.

2 investors

Psygen is a licensed manufacturer of pharmaceutical-grade psychedelic active pharmaceutical ingredients for academic research, clinical trials, and authorized medical use. The company serves researchers, physicians, and healthcare systems working within regulated compassionate-use and special access programs.

2 investors

Psilocybin biosynthesis platform that produces psychoactive molecular entities using yeast-based technology for pharmaceutical research and drug development.

2 investors

PTC is a global pharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare diseases who have few or no treatment options. It combines clinical and scientific expertise to bring these treatments to patients worldwide.

2 investors

PTM Therapeutics is a biotechnology company developing therapeutic candidates. The page does not provide sufficient detail about the company's specific focus areas or customer markets.

2 investors

Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system. The company pursues its own drug pipeline and partnerships with pharmaceutical companies across drug classes.

2 investors

PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness. Its lead programs target late-stage dry AMD/geographic atrophy and wet AMD, with prior Phase 1/2 studies conducted in Europe and the USA.

2 investors

Pumpkinseed builds a nanophotonic chip platform that reads proteins directly at single-molecule resolution using Raman spectroscopy, generating structured proteomic data. Its technology serves biopharma, biosecurity, and bio-AI applications, aiming to make the proteome readable for drug discovery, biomarker detection, and AI training datasets.

2 investors

PureSpectrum offers a market research technology platform, centered on its PureSpectrum Experience (PSX), that connects people, technology, and quality to support the research workflow for research stakeholders.

2 investors